At KalVista, we are focused on developing new oral treatments for HAE. Learn more about our clinical studies.

The KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.

Learn more about the
KONFIDENT-S extension study

The KONFIDENT Study (KVD900-301) was a Phase 3 clinical trial of sebetralstat for the oral, on-demand treatment of hereditary angioedema (HAE) attacks. The KONFIDENT Study is completed, and positive topline Phase 3 data results were reported in February 2024.

Learn more about
the KONFIDENT study